Introduction
Measurements of apolipoproteins A-I and B are of growing interest in the clinical and research laboratory because levels of these proteins in [5] . This is performed by adding increasing amounts of apolipoprotein, isolated lipoprotein or plasma to the immunoassay in the presence of a limiting amount of antibody. If the results are plotted on a linear log scale of percentage binding versus the log of the concentration of the competitor, the slopes of the linear portions of the curves can be compared. Additionally, logit transformation of the binding data will permit an analysis of the slopes of the competitors over a greater concentration range. In addition to comparisons of samples, standards and calibrators in the assay format, it is also important to establish whether storage of the samples or standards will result in changes in binding affinity.
Immunochemical heterogeneity of apolipoproteins A major stumbling block to the development of immunoassays with monoclonal reagents for total plasma levels of apo A-I or apo B is the observation that neither apo A-I or apo B appear to represent immunochemically homogenous proteins in lipoprotein particles. That is, many apo B-specific as well as apo A-I-specific monoclonal antibodies have been described that do not bind 100% of LDL or 100% of HDL, respectively [4, 5, 7, 12] . [7, 14] . In some instances it may be useful to combine monoclonal antibodies into 
